by Maria Zannes | Dec 12, 2024 | Press Releases
Noninvasive CyPath® Lung test for lung cancer contributes to growing revenues SAN ANTONIO, TX (Dec. 12, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage...
by Maria Zannes | Dec 5, 2024 | Press Releases
SAN ANTONIO, TX (Dec. 5, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, will join Federal Supply System (FSS) officials today in a joint...
by Maria Zannes | Nov 14, 2024 | Press Releases
bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024 Expanded CyPath® Lung test sales to physicians in Illinois, Alabama, and Louisiana; now receiving orders from physicians in 11 states Number of physician offices signed increased 75% over Q2 2024...
by Maria Zannes | Nov 8, 2024 | Articles, News
The Alamo City biotech has secured a key win in Japan that could make it a key player in a nearly billion-dollar industry. As published in the San Antonio Business Journal By W. Scott Bailey – Senior Reporter, San Antonio Business Journal BioAffinity Technologies Inc....
by Maria Zannes | Nov 4, 2024 | Press Releases
Dr. William Bauta, bioAffinity Senior Vice President of Research and Development and former Associate Director of Science at Genzyme and Ilex, steps into new role with the retirement of Dr. Vivienne Rebel SAN ANTONIO, Texas (Nov. 4, 2024) – bioAffinity Technologies,...
